Table A3.1 Summary statistics for each cancer site mapped: numbers of cases per ED or ward, ranges of SIRs and smoothed RRs for 1995-2007 | |||||||||
number of cases per ED/ward | SIR | smoothed RR (min-max) | |||||||
mean | (min-max) | ||||||||
cancer site | females | males | females | males | females | males | females | males | |
non-melanoma cancer of the skin | 12.5 | 14.2 | (0—315) | (0—333) | (0—6) | (0—5) | (0.6—1.9) | (0.6—2.1) | |
breast | 9.8 | — | (0—228) | — | (0—6) | — | (0.8—1.2) | — | |
colorectal | 4.3 | 5.4 | (0—89) | (0—124) | (0—9) | (0—5) | (0.8—1.2) | (0.8—1.4) | |
lung | 3.3 | 5.3 | (0—95) | (0—126) | (0—8) | (0—7) | (0.4—2.7) | (0.4—3.1) | |
prostate | — | 8.4 | — | (0—181) | — | (0—5) | — | (0.6—1.6) | |
non-Hodgkin's lymphoma | 1.2 | 1.3 | (0—26) | (0—30) | (0—22) | (0—13) | (0.9—1.2) | (0.8—1.1) | |
stomach | 0.9 | 1.5 | (0—29) | (0—39) | (0—23) | (0—20) | (0.5—2.0) | (0.6—1.8) | |
melanoma of the skin | 1.4 | 0.9 | (0—32) | (0—21) | (0—16) | (0—12) | (0.7—1.8) | (0.6—2.1) | |
bladder | 0.6 | 1.6 | (0—15) | (0—33) | (0—23) | (0—11) | (0.6—1.6) | (0.7—1.6) | |
head and neck | 0.6 | 1.4 | (0—18) | (0—35) | (0—28) | (0—11) | (0.6—1.9) | (0.6—2.8) | |
leukaemia | 0.8 | 1.1 | (0—16) | (0—32) | (0—30) | (0—13) | (0.9—1.1) | (0.8—1.3) | |
pancreas | 0.9 | 0.9 | (0—26) | (0—24) | (0—24) | (0—17) | (0.8—1.3) | (0.9—1.1) | |
kidney | 0.6 | 1.0 | (0—20) | (0—24) | (0—26) | (0—15) | (0.9—1.1) | (0.9—1.2) | |
oesophagus | 0.6 | 1.0 | (0—12) | (0—28) | (0—48) | (0—17) | (0.6—1.6) | (0.7—1.4) | |
ovary | 1.6 | — | (0—29) | — | (0—10) | — | (0.8—1.2) | — | |
brain and other central nervous system | 0.6 | 0.8 | (0—12) | (0—20) | (0—34) | (0—23) | (0.8—1.2) | (1.0—1.1) | |
corpus uteri | 1.3 | — | (0—28) | — | (0—16) | — | (0.8—1.3) | — | |
cervix uteri | 1.0 | — | (0—27) | — | (0—22) | — | (0.6—2.2) | — | |
SIR: standardised incidence ratios | |||||||||
RR: relative risk |